Metroplex Pulmonary and Sleep Center | McKinney, TX

Research site

(Unclaimed)

Location

4833 Medical Center Drive, Unit 6B, McKinney, Texas, United States of America

Site insights

Top conditions

Top treatments

Dupilumab

BMS-986278

INS018_055

Rocatinlimab

SAR443765

BLU-5937

SAR440340

AZLI

Levomilnacipran

Tiotropium Bromide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 24 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling

Refractory Chronic Cough

Drug: BLU-5937

Drug: Placebo

Locations recently updated

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling

Asthma

Drug: Placebo

Drug: Rocatinlimab

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this...

Enrolling

Bronchiectasis

Drug: Placebo

Drug: Itepekimab (SAR440340)

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling

Idiopathic Pulmonary Fibrosis

Drug: BMS-986278 Placebo

Drug: BMS-986278

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling

Progressive Pulmonary Fibrosis

Drug: BMS-986278 Placebo

Drug: BMS-986278

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Itepekimab (SAR440340)

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (AIRCULES)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Enrolling

Asthma

Drug: Placebo

Drug: Lunsekimig

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Inhaled Long-Acting Muscarinic Antagonist

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (ATLAS)

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling

Asthma

Drug: Placebo

Drug: Dupilumab

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).The primary objective is to evaluate...

Enrolling

Idiopathic Pulmonary Fibrosis (IPF)

Drug: Placebo

Drug: INS018_055

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in pati...

Active, not recruiting

MAC Lung Disease

Treatment Refractory MAC Lung Disease

Drug: Epetraborole

Drug: Placebo

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a...

Enrolling

Progressive Pulmonary Fibrosis

Interstitial Lung Disease

Device: Treprostinil Ultrasonic Nebulizer

Drug: Placebo

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment durat...

Enrolling

Idiopathic Pulmonary Fibrosis

Drug: TTI-101

Drug: Placebo

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Itepekimab SAR440340